143 related articles for article (PubMed ID: 35145218)
1. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
[TBL] [Abstract][Full Text] [Related]
3. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
5. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
[TBL] [Abstract][Full Text] [Related]
6. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
McKay RR; Hafron JM; Ferro C; Wilfehrt HM; Fitch K; Flanders SC; Fabrizio MD; Schweizer MT
Adv Ther; 2020 Dec; 37(12):4910-4929. PubMed ID: 33029725
[TBL] [Abstract][Full Text] [Related]
8. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
10. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
[TBL] [Abstract][Full Text] [Related]
14. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Marshall CH; Fu W; Wang H; Park JC; DeWeese TL; Tran PT; Song DY; King S; Afful M; Hurrelbrink J; Manogue C; Cotogno P; Moldawer NP; Barata PC; Drake CG; Posadas EM; Armstrong AJ; Sartor O; Antonarakis ES
Clin Cancer Res; 2021 Mar; 27(6):1623-1630. PubMed ID: 33451978
[TBL] [Abstract][Full Text] [Related]
16. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.
Caram MEV; Ross R; Lin P; Mukherjee B
JAMA Netw Open; 2019 Apr; 2(4):e192589. PubMed ID: 31002323
[TBL] [Abstract][Full Text] [Related]
19. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.
Francini E; Gray KP; Shaw GK; Evan CP; Hamid AA; Perry CE; Kantoff PW; Taplin ME; Sweeney CJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):420-427. PubMed ID: 30643173
[TBL] [Abstract][Full Text] [Related]
20. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
